Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
